Tandlægeselskabet Colosseum Roskilde ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 13.6% 10.4% 14.8% 28.4%  
Credit score (0-100)  0 16 22 13 1  
Credit rating  N/A BB BB BB B  
Credit limit (kDKK)  0.0 0.0 0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 3,923 5,568 5,999 4,657  
EBITDA  0.0 -276 17.8 -41.9 -1,455  
EBIT  0.0 -440 -295 -338 -1,765  
Pre-tax profit (PTP)  0.0 -483.3 -353.3 -371.4 -1,786.0  
Net earnings  0.0 -483.3 -353.3 -371.4 -1,786.0  
Pre-tax profit without non-rec. items  0.0 -483 -353 -371 -1,786  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 925 886 687 582  
Shareholders equity total  0.0 -443 -797 -1,168 -2,954  
Interest-bearing liabilities  0.0 800 1,441 0.0 0.0  
Balance sheet total (assets)  0.0 2,417 1,864 1,335 1,000  

Net Debt  0.0 207 1,173 -8.9 -45.8  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 3,923 5,568 5,999 4,657  
Gross profit growth  0.0% 0.0% 41.9% 7.8% -22.4%  
Employees  0 11 11 10 10  
Employee growth %  0.0% 0.0% 0.0% -9.1% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 2,417 1,864 1,335 1,000  
Balance sheet change%  0.0% 0.0% -22.9% -28.4% -25.1%  
Added value  0.0 -276.1 17.8 -25.4 -1,454.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 761 -352 -495 -415  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% -11.2% -5.3% -5.6% -37.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% -15.2% -10.7% -13.1% -54.5%  
ROI %  0.0% -43.1% -22.2% -41.0% 0.0%  
ROE %  0.0% -20.0% -16.5% -23.2% -153.0%  

Solidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% -15.5% -30.0% -46.8% -74.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -74.8% 6,600.1% 21.2% 3.2%  
Gearing %  0.0% -180.5% -180.9% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 12.4% 5.2% 4.6% 0.0%  

Liquidity 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.7 0.4 0.3 0.1  
Current Ratio  0.0 0.7 0.5 0.3 0.1  
Cash and cash equivalent  0.0 593.3 268.1 8.9 45.8  

Capital use efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 -561.2 -1,075.2 -1,240.9 -3,322.2  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 -25 2 -3 -145  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 -25 2 -4 -145  
EBIT / employee  0 -40 -27 -34 -177  
Net earnings / employee  0 -44 -32 -37 -179